KALA BIO financials
$0.5033+11.79%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $3.9M | $11.2M | $6.4M | $6.1M | — | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $1.3M | $7.1M | $3.2M | $4.1M | — | — |
| Gross margin | — | — | — | 34.2% | 63.5% | 50.1% | 66.9% | — | — |
| Operating income | -$39.2M | -$41.0M | -$39.7M | -$81.7M | -$128.9M | -$96.2M | -$88.2M | -$64.7M | -$39.9M |
| Net income | -$27.0M | -$38.5M | -$42.2M | -$44.8M | -$142.6M | -$104.3M | -$94.3M | -$66.7M | -$42.2M |
| Net margin | — | — | — | −1151.6% | −1268.7% | −1639.8% | −1553.3% | — | — |
| Diluted EPS | $-165.50 | $-507.50 | $-867.50 | $-1474.00 | $-5416.00 | $-4975.00 | $-6900.00 | $-6225.00 | $-9275.00 |
| EBITDA | -$37.4M | -$40.7M | -$39.6M | -$81.2M | -$129.3M | -$95.3M | -$87.4M | -$64.4M | -$39.2M |
| Operating cash flow | -$32.0M | -$29.4M | -$27.9M | -$78.9M | -$108.2M | -$90.7M | -$92.7M | -$54.1M | -$34.1M |
| Free cash flow | -$32.0M | -$29.6M | -$28.5M | -$79.2M | -$109.1M | -$92.6M | -$94.1M | -$55.7M | -$34.6M |
| Diluted shares | 0.2M | 0.1M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $7.6M | $51.2M | $50.9M | $70.5M | $92.1M | $77.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | $76.3M |
| Total debt | $0.00 | $30.4M | $34.2M | $43.5M | $78.9M | $99.4M |
| Total assets | $9.5M | $55.5M | $55.9M | $86.8M | $139.4M | $221.6M |
| Total liabilities | $2.5M | $43.2M | $48.4M | $67.8M | $122.6M | $121.6M |
| Shareholders' equity | $7.0M | $12.3M | $7.5M | $19.0M | $16.8M | $100.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology